Written questions by Evans.

Whether patients with recognised palliative or end-of-life care needs are subject to specific identification or prioritisation processes within accident and emergency departments.

Awaiting answer.

Whether he has made an assessment on the potential impact of introducing specific diagnostic or reporting time standards for patients with a limited or terminal prognosis.

Awaiting answer.

What guidance exists for NHS providers on the timely communication of significant diagnostic findings to patients and their families where deterioration or recurrence of cancer is suspected.

Awaiting answer.

How much undergraduate medical tariff funding has been withheld or unaccounted for, for each of the past five years.

Awaiting answer.

For what reason NHS England ceased collecting accountability reports on undergraduate medical tariff funding, and what alternative oversight arrangements are in place.

Awaiting answer.

How much and what proportion of undergraduate medical tariff funding is used to support (a) wider NHS service delivery and (b) educational activities.

Awaiting answer.

Whether NHS England continues to collect annual accountability reports from NHS trusts on the expenditure of undergraduate medical tariff funding.

Awaiting answer.

Whether the forthcoming Palliative Care and End-of-Life Care Modern Service Framework will include provisions relating to the timeliness of diagnostic results and communication for patients with a limited prognosis.

Awaiting answer.

What steps he is taking to ensure that undergraduate medical tariff funding is spent on frontline teaching and training for medical students.

Awaiting answer.

What assessment he has made of whether NHS England’s diagnostic imaging turnaround time guidance is sufficient to meet the needs of patients with a recognised terminal diagnosis.

Awaiting answer.

What steps he is taking to ensure consistent access across Integrated Care Boards to non-hormonal menopause treatments, including fezolinetant.

Awaiting answer.

What assessment he has made of levels of regional variation in access to fezolinetant across England.

Awaiting answer.

Whether he has had discussions with NHS England on access to fezolinetant within Leicester, Leicestershire and Rutland Integrated Care Board.

Awaiting answer.

Whether national guidance has been issued to Integrated Care Boards on the prescribing of fezolinetant following its approval for NHS use.

Awaiting answer.

What guidance exists on shared care arrangements for patients seeking to transition from privately obtained medication to NHS prescriptions where those treatments later become available on the NHS.

Awaiting answer.

What steps he is taking to ensure that patients are not disadvantaged when accessing NHS care after accessing treatment privately due to a previous lack of NHS availability.

Awaiting answer.

Pursuant to WPQ 106603 answered on 26 January 2026 about Marriage Relatives, what recent discussions the National Disease Registration Service has had with hospital trusts on improve the quality and completeness of data arising from health issues due to first cousin marriage.

Awaiting answer.

Pursuant to WPQ 9089 answered on 19 June 2026 about Steroid Drugs: Young People, if he will hold discussions with [i] local and national health bodies, [ii] academics and [iii] the Men's Health Str

Awaiting answer.

To ask the Secretary of State for Health and Social Care, with reference to the Prime Minister's oral contribution of 29 April 2026, official report, Volume 784, column 895, what is the evidential

Awaiting answer.

If he will hold discussions with (a) local and national health bodies, (b) academics and (c) the Men's Health Strategy Stakeholder Group on the issues surrounding Anabolic Steroids, IPEDs and SARMS

Awaiting answer.